Robert Hiltz, MD
Rheumatology · Cincinnati, OHNPI 1679549331
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,563 of the $164,562 with a category attached, or 82.4%. 22 manufacturers reported payments, led by AbbVie at 54.3% of the total. Reporting peaked in 2022 at $38,930 and has fallen 63.0% since, to $14,396 in 2025. Among rheumatology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,116 payments — averaging $147.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$89K
- Lilly USA, LLC$69K
- Amgen$3K
- UCB, Inc.$945
- Pfizer$395
- Genentech USA, Inc.$306
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,7002%
- Speaking & faculty fees$135,56382%
- Travel & lodging$9,5166%
- Food & beverage$15,94110%
- Education$8421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 509 | $89,286 |
| Lilly USA, LLC | 140 | $69,296 |
| Amgen(2 entities) | 206 | $2,698 |
| UCB, Inc. | 94 | $945 |
| Pfizer | 36 | $395 |
| Genentech USA, Inc. | 32 | $306 |
| Johnson & Johnson | 9 | $305 |
| Novartis | 33 | $286 |
| Regeneron Healthcare Solutions, Inc. | 11 | $177 |
| Mallinckrodt Hospital Products Inc. | 4 | $166 |
| E.r. Squibb & Sons, L.L.C. | 7 | $138 |
| Bristol Myers Squibb | 18 | $125 |
| Genentech, Inc. | 3 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Almatica Pharma LLC | 3 | $65 |
| Hikma Pharmaceuticals USA | 3 | $42 |
| Radius Health, Inc. | 2 | $34 |
| GSK | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,562 in reported general payments places this provider in the 95th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 61 | $560,903 |
| Humira(Cf) PenAdalimumab | 58 | $392,945 |
| RinvoqUpadacitinib | 46 | $279,695 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $216,156 |
| OtezlaApremilast | 33 | $195,852 |
| Taltz AutoinjectorIxekizumab | 26 | $172,195 |
| Actemra ActpenTocilizumab | 22 | $96,574 |
| Humira(Cf)Adalimumab | 13 | $95,129 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $74,731 |
| KevzaraSarilumab | 17 | $73,661 |
| Orencia ClickjectAbatacept | 11 | $63,679 |
| Teriparatide | 13 | $43,217 |
| Leflunomide | 289 | $12,507 |
| MethotrexateMethotrexate Sodium | 500 | $6,746 |
| Febuxostat | 55 | $6,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $89,286 | $374,82459 claims |
| AmgenOtezla | $2,698 | $195,85233 claims |
| UCB, Inc.Cimzia (2 Pack) | $945 | $74,73113 claims |
| Hikma Pharmaceuticals USAMitigare | $42 | $2,16512 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $17 | $1,04218 claims |
| Almatica Pharma LLCSertraline Hcl | $65 | $13124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Cincinnati
- Gregory DelorenzoCincinnati$1.3M
- David GreenblattCincinnati$56K
- Michael LuggenCincinnati$13K
- Emily BowersCincinnati$10K
- John HarleyCincinnati$9K
- Leonard CalabreseCleveland$1.9M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.